---
title: "Inhibikase Therapeutics, Inc. 1Q 2026: Revenue $0 Net income $(16.4) M, EPS $(0.10) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286155480.md"
description: "Inhibikase Therapeutics, Inc. reported no revenue for Q1 2026, with a net loss of $(16.4) M, widening from $(13.7) M a year earlier. Diluted EPS was $(0.10), an improvement from $(0.15) in Q1 2025. The company initiated a Phase 3 study for IKT-001 and is pursuing regulatory approvals in over 25 countries. Increased R&D spending is noted, with a funding runway expected to last at least 12 months as the company raises capital through an ATM program."
datetime: "2026-05-12T20:41:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286155480.md)
  - [en](https://longbridge.com/en/news/286155480.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286155480.md)
generator: "portal-rs"
---

# Inhibikase Therapeutics, Inc. 1Q 2026: Revenue $0 Net income $(16.4) M, EPS $(0.10) — 10-Q Summary

Inhibikase Therapeutics, Inc. reported results for the first quarter of 2026, posting no revenue, a net loss of $(16.4) M versus a $(13.7) M loss a year earlier, and diluted loss per share of $(0.10) compared with $(0.15) in 1Q 2025.

**Financial Highlights**

-   Revenue was $0 for 1Q 2026, unchanged from $0 in 1Q 2025.
-   Net income was a loss of $(16.4) M for 1Q 2026, compared with a $(13.7) M loss in 1Q 2025; net loss widened by $2.7M, or 19.8% YoY.
-   Diluted EPS was $(0.10) for 1Q 2026, versus $(0.15) in 1Q 2025.

**Business Highlights**

-   Clinical milestone: Initiated the pivotal global Phase 3 IMPROVE-PAH study; first patient enrolled in April 2026 and sites activating across 16 countries.
-   Regulatory progress: Pursuing approvals in 25+ countries and leveraging the FAST-EU pilot to accelerate multinational trial starts in Europe.
-   R&D and pipeline: Advancing IKT-001 (an imatinib prodrug) for pulmonary arterial hypertension; completed non-human primate safety and bioequivalence studies.
-   Operational posture: Increased R&D and SG&A spending to support Phase 3 and commercialization readiness; disclosed CRO/CMO commitments of approximately $67.6M through 2030.
-   Funding runway: Cash and marketable securities expected to support operations for at least 12 months; company is raising capital via an ATM program and prior public/private financings to fund trials.

Original SEC Filing: Inhibikase Therapeutics, Inc. \[ IKT \] - 10-Q - May. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IKT.US](https://longbridge.com/en/quote/IKT.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth](https://longbridge.com/en/news/295752640.md)
- [Inhibikase raises $50M to fund PAH program](https://longbridge.com/en/news/292740299.md)
- [Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages](https://longbridge.com/en/news/284878661.md)
- [Inhibikase rugi bersih Q2 FY26 melebar jadi USD 19,6 juta; belanja R&D melonjak 153,9% jadi USD 13,4 juta](https://longbridge.com/en/news/295574378.md)
- [Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering](https://longbridge.com/en/news/294255122.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**